Smith & Nephew
SNN
26.89
+0.02
+0.07%
Smith & Nephew
US · SNN
#1382 by market cap
Listed 1970
26.89
+0.02
+0.07%
Live - 5344 symbols - heartbeat 441s ago
· 2026-10-08 07:36
Pre-market
26.43
-1.71%
After-hours
26.89
0.00%
- Market cap
- 11.25B
- P/E (TTM)i
- 18.29
- P/Bi
- 2.17
- EPSi
- 1.43
- Div yieldi
- 2.91%
- 52W posi
- 8%
Reader sentiment
Are you bullish or bearish on SNN?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 3.17, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +6.09% YoY
Margins
- Gross margin
- 68.01%
- Operating margin
- 13.90%
- Net margin
- 10.14%
Key ratios & quality
- Enterprise valuei
- 13.87B
- PEG ratioi
- 0.45
- Altman Z-Scorei
- 3.17
PEG uses trailing P/E against the 3-year net income growth rate (40.99%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4.90B | 5.14B | 4.56B | 5.21B | 5.22B | 5.55B | 5.81B | 6.16B |
| Gross profit | 3.61B | 3.80B | 3.16B | 3.67B | 3.68B | 3.82B | 4.05B | 4.19B |
| Selling & admin expenses | 2.19B | 2.31B | 2.56B | 2.39B | 2.44B | 2.60B | 2.65B | 2.79B |
| Research & development | 246.00M | 292.00M | 307.00M | 356.00M | 345.00M | 339.00M | 289.00M | 296.00M |
| Operating profit | 997.00M | 990.00M | 295.00M | 682.00M | 634.00M | 620.00M | 860.00M | 857.00M |
| Pretax profit | 781.00M | 743.00M | 246.00M | 586.00M | 235.00M | 290.00M | 498.00M | 779.00M |
| Tax | 118.00M | 143.00M | -202.00M | 62.00M | 12.00M | 27.00M | 86.00M | 154.00M |
| Net profit | 663.00M | 600.00M | 448.00M | 524.00M | 223.00M | 263.00M | 412.00M | 625.00M |
| Basic EPS | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Diluted EPS | 1.51 | 1.37 | 1.02 | 1.19 | 0.51 | 0.60 | 0.94 | 1.43 |
| Line item | 2023-12 | 2024-06 | 2024-12 | 2025-06 | 2025-12 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | -- | -- | -- | -- | -- | -- |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | -- | -- | -- | -- | -- | -- |
| Pretax profit | -- | -- | -- | -- | -- | -- |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -- | -- | -- | -- | -- | -- |
| Basic EPS | -- | -- | -- | -- | -- | -- |
| Diluted EPS | -- | -- | -- | -- | -- | -- |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 3.08B | 3.22B | 4.66B | 4.42B | 3.86B | 4.03B | 4.42B | 4.10B |
| Cash & ST investments | 365.00M | 277.00M | 1.76B | 1.29B | 350.00M | 302.00M | 619.00M | 557.00M |
| Inventory | 1.40B | 1.61B | 1.69B | 1.84B | 2.21B | 2.40B | 2.39B | 2.12B |
| Total assets | 8.06B | 9.30B | 11.01B | 10.92B | 9.97B | 9.99B | 10.35B | 10.46B |
| Total current liabilities | 1.47B | 1.56B | 1.69B | 2.13B | 1.72B | 2.27B | 1.53B | 1.60B |
| Short-term debt | 164.00M | 72.00M | 337.00M | 491.00M | 160.00M | 765.00M | 63.00M | 150.00M |
| Long-term debt | 1.30B | 1.85B | 3.20B | 2.71B | 2.57B | 2.18B | 3.12B | 3.03B |
| Total liabilities | 3,185,000,000.00 | 4,158,000,000.00 | 5,733,000,000.00 | 5,352,000,000.00 | 4,707,000,000.00 | 4,770,000,000.00 | 5,089,000,000.00 | 5,168,000,000.00 |
| Total equity | 4.87B | 5.14B | 5.28B | 5.57B | 5.26B | 5.22B | 5.27B | 5.29B |
| Retained earnings | 4.63B | 4.85B | 4.96B | 5.23B | 5.03B | 4.91B | 5.02B | 5.32B |
| Line item | 2023-12 | 2024-06 | 2024-12 | 2025-06 | 2025-12 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 4.03B | 4.46B | 4.42B | 4.63B | 4.10B | 4.39B |
| Cash & ST investments | 302.00M | 568.00M | 619.00M | 676.00M | 557.00M | 754.00M |
| Inventory | 2.40B | 2.49B | 2.39B | 2.47B | 2.12B | 2.11B |
| Total assets | 9.99B | 10.54B | 10.35B | 10.69B | 10.46B | 11.01B |
| Total current liabilities | 2.27B | 1.78B | 1.53B | 1.54B | 1.60B | 2.05B |
| Short-term debt | 765.00M | 380.00M | 63.00M | 157.00M | 150.00M | 573.00M |
| Long-term debt | 2.18B | 3.14B | 3.12B | 3.15B | 3.03B | 3.08B |
| Total liabilities | 4,770,000,000.00 | 5,337,000,000.00 | 5,089,000,000.00 | 5,156,000,000.00 | 5,168,000,000.00 | 5,833,000,000.00 |
| Total equity | 5.22B | 5.21B | 5.27B | 5.54B | 5.29B | 5.18B |
| Retained earnings | 4.91B | 4.93B | 5.02B | 5.12B | 5.32B | 5.43B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 931.00M | 1.17B | 935.00M | 877.00M | 468.00M | 608.00M | 987.00M | 1.29B |
| Depreciation & amortization | -- | -- | -- | -- | -- | -- | -- | -- |
| Free cash flow | 584.00M | 760.00M | 492.00M | 469.00M | 110.00M | 181.00M | 606.00M | 852.00M |
| Dividends paid | -321.00M | -318.00M | -328.00M | -329.00M | -327.00M | -327.00M | -327.00M | -330.00M |
| Stock buybacks / issuance | -35.00M | -52.00M | -5.00M | 14.00M | -152.00M | 0 | 1.00M | -490.00M |
| Ending cash balance | 333.00M | 257.00M | 1.75B | 1.29B | 344.00M | 300.00M | 617.00M | 553.00M |
| Line item | 2023-12 | 2024-06 | 2024-12 | 2025-06 | 2025-12 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -- | -- | -- | -- | -- | -- |
| Depreciation & amortization | -- | -- | -- | -- | -- | -- |
| Free cash flow | -- | -- | -- | -- | -- | -- |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | -- | -- | -- | -- | -- | -- |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 13.93 | 11.98 | 8.60 | 9.66 | 4.12 | 5.02 | 7.86 | 11.84 |
| ROA %i | 8.33 | 6.91 | 4.41 | 4.78 | 2.14 | 2.64 | 4.05 | 6.01 |
| ROIC %i | 11.53 | 9.65 | 6.24 | 6.73 | 3.48 | 4.36 | 6.29 | 8.68 |
| 5-year avg ROE %i | 14.84 | 14.76 | 14.43 | 12.40 | 9.66 | 7.88 | 7.05 | 7.70 |
| EBIT margin %i | 17.37 | 15.92 | 7.04 | 13.03 | 6.25 | 7.73 | 11.46 | 15.54 |
| FCF / sales %i | 11.91 | 14.79 | 10.79 | 9.00 | 2.11 | 3.26 | 10.43 | 13.82 |
| Current ratioi | 2.10 | 2.06 | 2.76 | 2.08 | 2.25 | 1.77 | 2.89 | 2.57 |
| Quick ratioi | 1.12 | 0.95 | 1.64 | 1.11 | 0.87 | 0.65 | 1.19 | 1.16 |
| Debt / assetsi | 18.18 | 22.01 | 33.51 | 30.58 | 28.82 | 30.88 | 32.07 | 31.82 |
| LT debt / equityi | 26.69 | 38.42 | 63.52 | 51.15 | 51.57 | 44.45 | 61.88 | 60.07 |
| Interest coveragei | 12.00 | 10.91 | 4.28 | 7.30 | 3.58 | 3.09 | 3.96 | 5.35 |
| Revenue CAGR (3Y) %i | 1.91 | 3.24 | -1.46 | 2.05 | 0.50 | 6.76 | 3.69 | 5.73 |
| Net income CAGR (3Y) %i | 17.38 | -8.53 | -16.41 | -7.54 | -28.10 | -16.27 | -7.70 | 40.99 |
| FCF CAGR (3Y) %i | -4.57 | 18.48 | -11.67 | -7.05 | -47.50 | -28.35 | 8.92 | 97.86 |
| Line item | 2023-12 | 2024-06 | 2024-12 | 2025-06 | 2025-12 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 5.02 | 5.84 | 7.86 | 9.14 | 11.84 | 11.85 |
| ROA %i | 2.64 | 2.99 | 4.05 | 4.62 | 6.01 | 5.85 |
| ROIC %i | 4.36 | 4.87 | 6.29 | 6.74 | 8.68 | 8.42 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 7.73 | 8.49 | 11.46 | 13.02 | 15.54 | 15.43 |
| FCF / sales %i | 3.26 | 5.34 | 10.43 | 13.41 | 13.82 | 13.57 |
| Current ratioi | 1.77 | 2.51 | 2.89 | 3.00 | 2.57 | 2.14 |
| Quick ratioi | 0.65 | 1.08 | 1.19 | 1.37 | 1.16 | 1.09 |
| Debt / assetsi | 30.88 | 34.67 | 32.07 | 32.30 | 31.82 | 34.37 |
| LT debt / equityi | 44.45 | 62.92 | 61.88 | 59.56 | 60.07 | 62.01 |
| Interest coveragei | 3.09 | 3.26 | 3.96 | 4.63 | 5.35 | 5.55 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Diversified
- Orthopaedics is the largest reported line at 39.54% of revenue, across 3 reported segments.
- No single line clears half of revenue; Sports Medicine & Ear, Nose & Throat (ENT) is next at 31.38%, spreading the business across more than one real driver.
Revenue breakdown most recent period
Business
Orthopaedics39.54%
Sports Medicine & Ear, Nose & Throat (ENT)31.38%
Advanced Wound Management29.09%
Region
United States of America53.63%
Established Markets24.03%
Emerging Markets16.27%
United Kingdom3.99%
China2.08%
Quote time 2026-10-08 07:36:10 · For reference only, not investment advice and not tailored to your situation.